WuXi Biologics
WuXi Biologics is making headlines in 2025 with strong financial growth, global manufacturing expansion, and technological innovation. The company reported robust revenue gains, supported by high demand for its CRDMO services and efficient capacity utilization. A major milestone came with the EMA approval of its Dundalk, Ireland site, enabling its first commercial launch from the facility and advancing its Global Dual Sourcing Strategy.
On the innovation front, WuXi Biologics continues to strengthen its platforms for complex biologics, including antibody-drug conjugates (ADCs) and bispecific/multispecific T-cell engagers. Its partnerships are advancing new molecules into clinical trials, including the fourth WuXi-originated TCE program, scheduled for early 2025. Recognition as “CDMO of the Year” and other industry awards highlight client trust, quality systems, and strong execution. Positioned across the full biologics lifecycle, WuXi Biologics is cementing its role as a global leader in biologics development and manufacturing.
“From Ireland to innovation, WuXi Biologics is powering the future of complex biologics with scale, trust, and technology.”
2025 Revenue Comparison: Top 10 Global CDMOs
WuXi Biologics continues to reinforce its position as one of the world’s top five CDMOs by revenue in 2024 and 2025, standing alongside industry giants such as Lonza, Thermo Fisher Scientific, Samsung Biologics, and Catalent. The company achieved significant regulatory milestones, with five of its manufacturing facilities in Wuxi, China—two drug substance sites (MFG1, MFG5) and three drug product sites (DP1, DP2, DP5)—successfully passing the FDA’s Pre-License Inspection without any critical issues or data integrity concerns.
Further expanding its global footprint, WuXi Biologics commenced construction of a 95,000-square-meter microbial manufacturing facility in Chengdu’s Wenjiang district, expected to begin GMP production by the end of 2026. In parallel, the company is building a 30,000-square-meter modular biologics drug product facility in Singapore, which will integrate into its regional CRDMO hub to support growing international demand.
Market revenue of the top 10 CDMOs globally in 2025
Fig 12: 2025 market revenue of CDMOs
Market revenue of WuXi Biologics
WuXi Biologics has demonstrated steady revenue growth over the past five years, reflecting strong demand for its biologics development and manufacturing services. For 2025, the company projects full-year revenue of USD 1.99–2.04 billion (RMB 14.56–14.94 billion), representing a 14%–16% increase compared to 2024. This outlook follows robust interim results, with revenue rising 16.1% year-over-year in the first half of 2025. The strong performance prompted WuXi Biologics to raise its full-year growth guidance, underscoring its continued momentum in the global biologics market.
"WuXi Biologics projects 14–16% revenue growth in 2025 after strong interim results, underscoring its sustained momentum in the global biologics market."
Six-year market revenue of WuXi Biologics (2020- H1 2025)
Fig 13: Market revenue of WuXi Biologics
WuXi Biologics Pipeline Analysis: Driving Innovation in Next-Generation Biologics
Unlike traditional pharmaceutical companies, WuXi Biologics does not maintain a proprietary drug pipeline. Instead, as a Contract Research, Development, and Manufacturing Organization (CRDMO), its “pipeline” reflects the hundreds of integrated projects it supports for global biopharma partners. The company’s business model is built on enabling clients—ranging from startups to large pharmaceutical firms—to discover, develop, and manufacture biologics, including next-generation therapies.
This approach has created a diverse and expansive portfolio across multiple therapeutic areas and modalities. As of June 30, 2025, WuXi Biologics was advancing 864 integrated projects, with 86 new programs added in the first half of 2025 alone.
Key Features of the Pipeline
· Broad therapeutic modalities:
· Bispecific and multispecific antibodies – representing a large share of new projects, designed to engage multiple disease targets simultaneously.
· Antibody-drug conjugates (ADCs) – targeted cancer therapies that link antibodies to cytotoxic agents.
· Fusion proteins and vaccines – including programs developed through its subsidiary, WuXi Vaccines.
Strategic growth initiatives:
· “Win-the-Molecule” strategy – focuses on onboarding external projects, including late-stage and commercial programs, to accelerate growth and revenue.
· Proprietary technology platforms – such as WuXia™ (cell line development) and WuXiBody™ (bispecific antibody design), which attract and secure new client partnerships.
Through this model, WuXi Biologics has built one of the industry’s broadest and most diversified pipelines, positioning itself as a global leader in supporting the development of innovative biologics.
* Other Protein-based Biologics- A varied category that makes up the remainder of the portfolio